Jia Luo

Also affiliated with Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 19 papers. Top paper: “Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade”.

Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0047

N/A

7.6DataRank · unranked

340 citations

Jia Luo, Song Wu, Han Si, Chen Gao, Wenjing Xu +10 more

Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer

Nature Cancer(2022)10.1038/s43018-022-00416-8

N/A

0.888DataRank · unranked

372 citations

Jia Luo, Andrew Aukerman, Jacklynn V. Egger, Christopher J. Fong, Natally Horvat +16 more

Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0596

N/A

0.823DataRank · unranked

241 citations

Hira Rizvi, Jacklynn V. Egger, Isabel R. Preeshagul, Jedd D. Wolchok, Matthew D. Hellmann +1 more

Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer

Cancer Cell(2024)10.1016/j.ccell.2023.12.013

N/A

0.788DataRank · unranked

190 citations

Adam J. Schoenfeld, Darwin Ye, George Fromm, Hira Rizvi, Xiang H.-F. Zhang +28 more

Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3418

N/A

0.723DataRank · unranked

123 citations

Barzin Y. Nabet, Hira Rizvi, Aadel A. Chaudhuri, Daniel K. Wells, Mark Dunphy +30 more

Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2021.06.024

N/A

0.708DataRank · unranked

111 citations

Jason Beattie, Paige Fuentes, Hira Rizvi, Jacklynn V. Egger, Jeffrey A. Kern +8 more

Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non–Small Cell Lung Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0921

N/A

0.672DataRank · unranked

87 citations

Victoria Martucci, Zoe Quandt, Stefan Groha, Megan H. Murray, Christine M. Lovly +16 more

Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0419

N/A

0.635DataRank · unranked

68 citations

Anh Tuan Luu, Jia Luo, Hira Rizvi, Andrew J. Plodkowski, Mustafa Sakhi +11 more

Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-001007

N/A

0.614DataRank · unranked

59 citations

Biagio Ricciuti, E. Jimenez-Aguilar, Fangxin Hong, Zihan Wei, Mizuki Nishino +10 more

Deciphering radiological stable disease to immune checkpoint inhibitors

Annals of Oncology(2022)10.1016/j.annonc.2022.04.450

N/A

0.590DataRank · unranked

50 citations

Song Wu, Hira Rizvi, Q. Zhang, Jacklynn V. Egger, Juan C. Osorio +14 more

The BRD4–NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma

Cancer Research(2023)10.1158/0008-5472.can-23-2545

N/A

0.553DataRank · unranked

39 citations

Julianna Huang, Luke Wojenski, Yeying Huang, Prafulla C. Gokhale, Brittaney A. Leeper +14 more

Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1207

N/A

0.542DataRank · unranked

36 citations

Biagio Ricciuti, Chaitanya Bandlamudi, Daniel M. Muldoon, Hira Rizvi, Arielle Elkrief +23 more

Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas

Nature Communications(2022)10.1038/s41467-022-33719-6

N/A

0.449DataRank · unranked

19 citations

Jia Luo, Ni Ai, Rachel Kim, Linda S. Ahn, Anup Biswas +10 more

EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes

Cancer Research(2023)10.1158/0008-5472.can-23-1475

N/A

0.434DataRank · unranked

17 citations

R. Taylor Durall, Nhi M. Luong, Hans J. Hertzler, Julianna Huang, Prafulla C. Gokhale +21 more

Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.12.022

N/A

0.416DataRank · unranked

15 citations

Michelle Sanchez, Elinton Lee, Hans J. Hertzler, Nhi M. Luong, Emanuele Mazzola +17 more

Beyond steroids: Immunosuppressants in steroid-refractory/resistant immune related adverse events.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9092

N/A

0.233DataRank · unranked

2 citations

Jason Beattie, Paige Fuentes, Hira Rizvi, Jacklynn V. Egger, Jeffrey A. Kern +8 more

Novel BRD2::NUTM1 Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report

JTO Clinical and Research Reports(2023)10.1016/j.jtocrr.2023.100625

N/A

0DataRank · unranked

2 citations

Justin J. Kim, Yeying Huang, R. Taylor Durall, Simone Becker, Stephanie Canty +6 more

Data from Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non–Small Cell Lung Cancer

(2023)10.1158/1078-0432.c.6530652.v1

N/A

0DataRank · unranked

0 citations

Victoria Martucci, Zoe Quandt, Stefan Groha, Megan H. Murray, Christine M. Lovly +16 more

Association of prior radiation dose to the cardiopulmonary system with COVID-19 outcomes in patients with cancer

Radiotherapy and Oncology(2021)10.1016/j.radonc.2021.06.002

N/A

0DataRank · unranked

3 citations

Maria Thor, Narek Shaverdian, Jacob Y. Shin, Philip Gilbo, Jia Luo +3 more